The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma
出版年份 2015 全文链接
标题
The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma
作者
关键词
-
出版物
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 290, Issue 50, Pages 29854-29868
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2015-10-20
DOI
10.1074/jbc.m115.664953
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Multiple Myeloma, Version 1.2013
- (2017) Kenneth C. Anderson et al. Journal of the National Comprehensive Cancer Network
- A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease
- (2015) J. Paton-Hough et al. BONE
- Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation
- (2014) Shuji Ozaki et al. ACTA HAEMATOLOGICA
- Modulation of NRF2 signaling pathway by nuclear receptors: Implications for cancer
- (2014) Akhileshwar Namani et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Nrf2, a Regulator of the Proteasome, Controls Self-Renewal and Pluripotency in Human Embryonic Stem Cells
- (2014) Jiwon Jang et al. STEM CELLS
- RARAfusion genes in acute promyelocytic leukemia: a review
- (2014) Etienne De Braekeleer et al. Expert Review of Hematology
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
- (2013) M. Wang et al. BLOOD
- Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis
- (2013) Samantha Pozzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
- (2013) Robert Z. Orlowski CANCER CELL
- Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
- (2013) Chungyee Leung-Hagesteijn et al. CANCER CELL
- Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
- (2013) R. Niesvizky et al. CLINICAL CANCER RESEARCH
- The emerging role of the Nrf2-Keap1 signaling pathway in cancer
- (2013) M. C. Jaramillo et al. GENES & DEVELOPMENT
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
- (2013) C C Bjorklund et al. LEUKEMIA
- Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
- (2013) H. A. F. Stessman et al. MOLECULAR CANCER THERAPEUTICS
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Sequence analysis of -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
- (2012) D. I. Lichter et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
- (2012) D. J. Kuhn et al. BLOOD
- Nrf2-dependent Induction of Proteasome and Pa28αβ Regulator Are Required for Adaptation to Oxidative Stress
- (2012) Andrew M. Pickering et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Small Molecule Modulators of Keap1-Nrf2-ARE Pathway as Potential Preventive and Therapeutic Agents
- (2012) Sadagopan Magesh et al. MEDICINAL RESEARCH REVIEWS
- Latest advances and current challenges in the treatment of multiple myeloma
- (2012) Anuj Mahindra et al. Nature Reviews Clinical Oncology
- Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha
- (2012) B. N. Chorley et al. NUCLEIC ACIDS RESEARCH
- New Proteasome Inhibitors in Myeloma
- (2012) Panisinee Lawasut et al. Current Hematologic Malignancy Reports
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland
- (2011) I. Hrusovsky et al. ONCOLOGY
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- A Novel Testis-specific GTPase Serves as a Link to Proteasome Biogenesis: Functional Characterization of RhoS/RSA-14-44 in Spermatogenesis
- (2010) Ning Zhang et al. MOLECULAR BIOLOGY OF THE CELL
- Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells
- (2010) Senthil K. Radhakrishnan et al. MOLECULAR CELL
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Catalytic Mechanism and Assembly of the Proteasome
- (2009) António J. Marques et al. CHEMICAL REVIEWS
- The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02
- (2009) S. LÜ et al. International Journal of Laboratory Hematology
- Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
- (2009) Jacob P. Laubach et al. LEUKEMIA & LYMPHOMA
- Molecular mechanisms of proteasome assembly
- (2009) Shigeo Murata et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
- (2008) R. Z. Orlowski et al. CLINICAL CANCER RESEARCH
- Point Mutation of the Proteasome 5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line
- (2008) S. Lu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now